ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annu... (and hasexclusive rights to certain thera...)

HOME >> BIOLOGY >> TECHNOLOGY

ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting

Date:12/11/2007

and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

ThromboGenics NV

Campus Gasthuisberg

Herestraat 49

B-3000 Leuven

Belgium

Tel: +32(0)16-34-61-94

http://www.thrombogenics.com

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.

For more information:

ThromboGenics NV

Professor Desire Collen

Chief Executive Officer

Tel : +32(0)16-34-61-94

Dr. Patrik De Haes

Chief Operating Officer

Tel : +32(0)16-34-61-94

Stuart Laermer

Chief Business Officer

ThromboGenics Inc.

Tel: +1-212-201-0920